- Home
- CB vs CINGW Comparison
CB vs CINGW Comparison
Compare CB & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CB
- CINGW
- Stock Information
- Founded
- CB 1985
- CINGW N/A
- Country
- CB Switzerland
- CINGW United States
- Employees
- CB N/A
- CINGW 13
- Industry
- CB Property-Casualty Insurers
- CINGW Biotechnology: Pharmaceutical Preparations
- Sector
- CB Finance
- CINGW Health Care
- Exchange
- CB Nasdaq
- CINGW Nasdaq
- Market Cap
- CB 114.2B
- CINGW N/A
- IPO Year
- CB 1993
- CINGW 2021
- Fundamental
- Price
- CB $273.24
- CINGW $0.04
- Analyst Decision
- CB Buy
- CINGW
- Analyst Count
- CB 20
- CINGW 0
- Target Price
- CB $289.00
- CINGW N/A
- AVG Volume (30 Days)
- CB 1.6M
- CINGW N/A
- Earning Date
- CB 01-28-2025
- CINGW N/A
- Dividend Yield
- CB 1.33%
- CINGW N/A
- EPS Growth
- CB 44.45
- CINGW N/A
- EPS
- CB 24.43
- CINGW N/A
- Revenue
- CB $54,697,000,000.00
- CINGW N/A
- Revenue This Year
- CB N/A
- CINGW N/A
- Revenue Next Year
- CB $6.63
- CINGW N/A
- P/E Ratio
- CB $11.18
- CINGW N/A
- Revenue Growth
- CB 13.16
- CINGW N/A
- 52 Week Low
- CB $220.21
- CINGW N/A
- 52 Week High
- CB $302.05
- CINGW N/A
- Technical
- Relative Strength Index (RSI)
- CB 36.80
- CINGW N/A
- Support Level
- CB $271.28
- CINGW N/A
- Resistance Level
- CB $277.82
- CINGW N/A
- Average True Range (ATR)
- CB 4.62
- CINGW 0.00
- MACD
- CB -0.86
- CINGW 0.00
- Stochastic Oscillator
- CB 11.45
- CINGW 0.00
About CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About CINGW Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.